Core Insights - The company is expected to achieve profitability by 2025, with significant breakthroughs in international expansion and promising clinical data for its product, Westoroni, in the pancreatic cancer field [1][2]. Financial Performance - The company's revenue forecast for 2025 is projected at 910 million yuan, representing a year-on-year growth of 38.32% [2]. - The net profit attributable to shareholders is expected to be 53.46 million yuan, marking a turnaround from previous losses [2]. - Key products, including Sigleth sodium, have seen a sales revenue increase of approximately 123% year-on-year, while Sidabamine, despite facing price reductions from insurance, still achieved a 16% growth [2]. Recent Developments - On February 10, 2026, the company announced progress in its international expansion, granting exclusive rights for Sidabamine to Russian pharmaceutical company Nizhpharm in the CIS and Central Asia, which includes an upfront payment of 10 million yuan [3]. - The updated Phase II clinical data for Westoroni in combination chemotherapy shows a 50% objective response rate (ORR) and a median progression-free survival (mPFS) of 9.1 months, supporting further development [3]. Stock Performance - Over the past week (February 5 to 11, 2026), the company's stock price fluctuated between a high of 32.47 yuan and a low of 30.75 yuan, with a total decline of 0.76% [4]. - On February 10, the stock price increased by 1.28%, with a net inflow of 28.19 million yuan from major funds; however, it closed at 31.21 yuan on February 11, down 1.73% for the day [4]. - The financing balance has been increasing, with a recent growth of 5.57% over the past five days [4].

Group 1 - The core viewpoint of the report is that Fosun Pharma (02196) is expected to achieve net profits of 3.32 billion yuan, 4.68 billion yuan, and 4.77 billion yuan from 2025 to 2027, with year-over-year growth rates of +19.9%, +40.8%, and +2.1% respectively, indicating a positive long-term outlook and a "buy" rating maintained by Yuanta Securities [1] - The company’s subsidiary, Fuhong Hanlin, has granted Eisai the rights for the development, production, and commercialization of the PD-1 monoclonal antibody, Surulitinib, in Japan, with a total upfront payment and milestone payments potentially reaching up to $155.01 million [1] - The upfront payment includes $75 million and up to $80.01 million in regulatory milestone payments, along with potential sales milestone payments of up to $23.33 million based on annual net sales in Japan [1] Group 2 - Surulitinib, a PD-1 monoclonal antibody developed by the company, was launched in China in March 2022 and is expected to generate revenue of 1.31 billion yuan in 2024, reflecting a year-over-year growth of +17.2% [2] - The product has received EU approval for first-line treatment of SCLC in February 2025, making it the first PD-1 monoclonal antibody approved in the EU for this indication, and has also been approved in several other countries, enhancing its international market presence [2] - The company is actively expanding into new markets and indications, with ongoing clinical trials for Surulitinib in various cancers and a new application for gastric cancer treatment expected to be accepted by the Chinese regulatory authority by December 2025 [3]